Free Trial
→ Executive Order 14241 Unleashes Trump’s New Dollar (From Porter & Company) (Ad)tc pixel
NASDAQ:BLRX

BioLineRx Q3 2026 Earnings Date & Estimates

BioLineRx logo
$1.49 -0.09 (-5.76%)
As of 03:03 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BioLineRx is estimated to report Q3 2026 earnings on Monday, November 23, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from BioLineRx in Q3 2026

BioLineRx is expected to post earnings of -$0.39 per share on revenue of $358 thousand. In the same quarter a year earlier BioLineRx reported -$0.22 per share on revenue of $427 thousand. BioLineRx last reported on August 28, 2026, posting -$0.77 per share and missing the -$0.15 consensus estimate. BioLineRx has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.39
Expected Revenue
$358 thousand
Prior-Year EPS
-$0.22
Prior-Year Revenue
$427 thousand
Expected Revenue Growth
-16.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.77 (Missed by -$0.62)
Last Quarter Revenue
$294 thousand
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

BioLineRx Q3 2026 Earnings FAQ

BioLineRx (NASDAQ:BLRX) is estimated to report Q3 2026 earnings on Monday, November 23, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

BioLineRx's Q3 2026 earnings conference call is scheduled for Monday, November 23, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect BioLineRx to post earnings of -$0.39 per share for Q3 2026.

The consensus revenue estimate for BioLineRx is $358 thousand for Q3 2026.

BioLineRx Earnings Headlines

BioLineRx Ltd. And Hemispherian AS Present Preclinical Data Demonstrating Synergy Of GLIX1 With PARP Inhibitors In HR-Proficient Ovarian Cancer At ESMO 2026
October 23, 2026  |  marketscreener.comM
BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026
October 23, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biolinerx-and-hemispherian-present-preclinical-data-demonstrating-synergy-of-glix1-with-parp-inhibitors-in-hr-proficient-ovarian-cancer-at-esmo-2026-302917934.html
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
November 10 at 1:00 AM  |  American Alternative (Ad)
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
October 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biolinerx-and-hemispherian-announce-two-glix1-presentations-at-the-31st-society-for-neuro-oncology-sno-annual-meeting--education-day-302902311.html
BioLineRx Shareholders Approve Board, Capital and Compensation Moves at 2026 AGM
September 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/biolinerx-shareholders-approve-board-capital-and-compensation-moves-at-2026-agm?utm_source=marketbeat.com&utm_medium=referral
BioLineRx And Hemispherian To Present GLIX1 Data At EANO 2026; Stock Up
September 10, 2026  |  rttnews.comhttps://www.rttnews.com/3690000/biolinerx-and-hemispherian-to-present-glix1-data-at-eano-2026-stock-up.aspx
See More BioLineRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioLineRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioLineRx and other key companies, straight to your email.

About BioLineRx

BioLineRx (NASDAQ:BLRX) is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious medical conditions. The company is headquartered in Modi’in, Israel, and is listed on the Nasdaq Capital Market under the symbol BLRX.

BioLineRx’s primary product is APHEXDA (motixafortide), a CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in combination with filgrastim to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma. Motixafortide was originally developed as BL-8040 and remains the company’s leading clinical and commercial asset.

In addition to its multiple myeloma indication, BioLineRx has evaluated motixafortide in clinical studies involving pancreatic cancer and other hematologic and solid-tumor settings. The company’s operations and clinical development activities have included Israel, the United States and international research sites. Philip Serlin serves as BioLineRx’s chief executive officer.

View BioLineRx Profile
Earnings Tools